These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 30191846)
1. Targeted therapy: a potential oversight in trial protocol. Moorthy T Lancet Oncol; 2018 Sep; 19(9):e439. PubMed ID: 30191846 [No Abstract] [Full Text] [Related]
2. Maurie Markman on the Groundbreaking TAPUR Trial. Markman M Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751 [No Abstract] [Full Text] [Related]
3. American Society of Clinical Oncology Developing First Clinical Trial. Brower V J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625 [No Abstract] [Full Text] [Related]
4. Precision oncology: A new era of cancer clinical trials. Renfro LA; An MW; Mandrekar SJ Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624 [TBL] [Abstract][Full Text] [Related]
5. Strides in melanoma announced: maximizing value comes next. Tuma RS J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727 [No Abstract] [Full Text] [Related]
6. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Do K; O'Sullivan Coyne G; Chen AP Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298 [TBL] [Abstract][Full Text] [Related]
7. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy. Farwell MD; Clark AS; Mankoff DA JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243 [No Abstract] [Full Text] [Related]
8. BRAF molecular testing in cytopathology: Implications for diagnosis, prognosis, and targeted therapeutics. Bergdorf KN; Lee LA; Weiss VL Cancer Cytopathol; 2020 Jan; 128(1):9-11. PubMed ID: 31765065 [No Abstract] [Full Text] [Related]
9. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062 [TBL] [Abstract][Full Text] [Related]
10. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291 [TBL] [Abstract][Full Text] [Related]
12. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. Kato S; Subbiah V; Kurzrock R J Natl Compr Canc Netw; 2017 Jul; 15(7):863-866. PubMed ID: 28687573 [No Abstract] [Full Text] [Related]
13. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Lin PS; Semrad TJ Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315 [TBL] [Abstract][Full Text] [Related]
14. BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens. Lee PJ; Dennis K; Madan R; Fan F Acta Cytol; 2019; 63(1):10-16. PubMed ID: 30396186 [TBL] [Abstract][Full Text] [Related]
15. [Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)]. Matsui J; Funahashi Y Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):162-6. PubMed ID: 24107519 [No Abstract] [Full Text] [Related]
16. Drug development: a chance of survival. Hoag H Nature; 2014 Nov; 515(7527):S118-20. PubMed ID: 25407709 [No Abstract] [Full Text] [Related]
17. Personalized Medicine: Genomics Trials in Oncology. Hayes DF; Schott AF Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Chen G; Davies MA Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945 [TBL] [Abstract][Full Text] [Related]